Millions of patients around the world are suffering from the dramatic effects of fibrotic diseases.
Whether the damage occurs in the liver, as in non-alcoholic steatohepatitis (NASH); in the lung, as in idiopathic pulmonary fibrosis (IPF); in the kidney, as in chronic kidney disease (CKD); in the skin, as in scleroderma; or in the gut, as in inflammatory bowel disease (IBD); the consequences of fibrosis are devastating to patients’ health, and may ultimately necessitate drastic measures such as organ transplant, or tragically, cause an untimely death.